Glaucoma surgery
US8715266B2 · kind B2 · utility
28Cited by
0References
16Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 11, 2009 |
| Grant date | May 6, 2014 |
| Priority date | — |
| Expiry date | Jul 23, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Eye diseases such as glaucoma can be treated using a composition containing cross-linked hyaluronic acid or a cross-linked salt of hyaluronic acid such as sodium hyalurate. The composition can be a monophasic gel. The composition can include a cross-linking agent such as 1,4-butanediol diglycidylether. The composition can contains about 2.25% (w/w) of the salt of hyaluronic acid. The composition can have a cross-linking rate of about 0.5 to 50%.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.